DV
Dividend Vision

GANX — Gain Therapeutics Inc

Gain Therapeutics Inc (GANX)

Total return is -81.1% over the past 5.4 years, 194.7 points behind SPY at 113.6%. Its deepest 1-year drawdown was 62.0%.

GANX is an equity fund focused on therapeutic investments, established in March 2021. The fund lacks a documented distribution rate, expense ratio, and published assets under management, suggesting it may be a small or newly launched offering with limited publicly available performance data. This fund structure may appeal to investors seeking exposure to the therapeutics sector, though the absence of standard dividend metrics indicates it is not positioned as an income-focused vehicle.

GANX key facts

Asset type
Stock
Asset class
Equity
Inception date
03/18/2021
Last close
$2.12
Market cap
$72,938,408
Average volume
519002.0
Beta
0.157
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.58